RIYADH: Cialis drug is expected to record annual revenues of around SR100 million ($27 million), after the acquisition of prescription rights of the drug in Saudi Arabia.

The deal was signed on Dec. 27 between Eli Lilly and Saudi Chemical Company Holding, where its subsidiary AJA Pharmaceutical Industries will become the manufacturer and supplier for Cialis in the Kingdom.

Cialis is a medication used to treat male sexual function problems and acts as a relaxant for muscles of the blood vessels.

The Saudi-based company said in a bourse statement that transaction closure is subject to approvals from necessary governmental bodies.

 

Copyright: Arab News © 2021 All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.